Combination omalizumab and mepolizumab therapy for refractory allergic bronchopulmonary aspergillosis

Journal of Allergy and Clinical Immunology: In Practice

Volumn 5, Issue 4, 2017, Pages 1137-1139

  Altman, Matthew C ^a,b   Lenington, Jake ^a   Bronson, Steve ^a   Ayars, Andrew G ^a,b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ITRACONAZOLE; MEPOLIZUMAB; OMALIZUMAB; PREDNISONE; SALBUTAMOL; VORICONAZOLE; ANTIALLERGIC AGENT; ANTIFUNGAL AGENT; MONOCLONAL ANTIBODY;

ADULT; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ARTICLE; ASTHMA; BRONCHIECTASIS; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ESOPHAGUS CANDIDIASIS; FEMALE; FORCED VITAL CAPACITY; HEMOPTYSIS; HUMAN; HYPERGLYCEMIA; MIDDLE AGED; NOSE OBSTRUCTION; PAKISTAN; SPIROMETRY; WEIGHT GAIN; WHEEZING; ASPERGILLUS FUMIGATUS; COMBINATION DRUG THERAPY; DRUG RESISTANCE; HYPERSENSITIVITY; IMMUNOLOGY; RECURRENT DISEASE; RESPIRATORY FAILURE;

ADRENAL CORTEX HORMONES; ANTI-ALLERGIC AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIFUNGAL AGENTS; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASPERGILLUS FUMIGATUS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERSENSITIVITY; MIDDLE AGED; OMALIZUMAB; RECURRENCE; RESPIRATORY INSUFFICIENCY;

EID: 85014467597     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2017.01.013     Document Type: Article

References (9)

1. Greenberger, P.A., Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 110 (2002), 685–692.
2. Agarwal, R., Chakrabarti, A., Shah, A., Gupta, D., Meis, J.F., Guleria, R., et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 43 (2013), 850–873.
3. Knutsen, A.P., Slavin, R.G., Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis. Clin Dev Immunol 2011 (2011), 1–13.
4. Moss, R.B., Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis. Eur Respir J 43 (2013), 1487–1500.
5. Stevens, D.A., Moss, R.B., Kurup, V.P., Knutsen, A.P., Greenberger, P., Judson, M.A., et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis—state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 37 (2003), S225–S264.
6. Collins, J., deVos, G., Hudes, G., Rosenstreich, D., Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab. J Asthma Allergy 5 (2012), 65–70.
7. Aydın, Ö., Sözener, Z.Ç., Soyyiğit, Ş., Kendirlinan, R., Gençtürk, Z., Mısırlıgil, Z., et al. Omalizumab in the treatment of allergic bronchopulmonary aspergillosis: one center's experience with 14 cases. Allergy Asthma Proc 36 (2015), 493–500.
8. Tillie-Leblond, I., Germaud, P., Leroyer, C., Tétu, L., Girard, F., Devouassoux, G., et al. Allergic bronchopulmonary aspergillosis and omalizumab. Allergy 66 (2011), 1254–1256.
9. Voskamp, A.L., Gillman, A., Symons, K., Sandrini, A., Rolland, J.M., O'Hehir, R.E., et al. Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract 3 (2015), 192–199.